tiprankstipranks
Peptidream Inc. (JP:4587)
TSE/TYO:4587
Holding JP:4587?
Track your performance easily

Peptidream (4587) Stock Price & Analysis

1 Followers

4587 Stock Chart & Stats


Options Prices

Currently, No data available
---

Ownership Overview

2.27%94.83%
Insiders
― Other Institutional Investors
94.83% Public Companies and
Individual Investors

4587 FAQ

What was Peptidream Inc.’s price range in the past 12 months?
Peptidream Inc. lowest stock price was ¥1181.50 and its highest was ¥3060.00 in the past 12 months.
    What is Peptidream Inc.’s market cap?
    Currently, no data Available
    When is Peptidream Inc.’s upcoming earnings report date?
    Peptidream Inc.’s upcoming earnings report date is Feb 05, 2025 which is in 52 days.
      How were Peptidream Inc.’s earnings last quarter?
      Peptidream Inc. released its earnings results on Nov 13, 2024. The company reported -¥2.35 earnings per share for the quarter, missing the consensus estimate of ¥3.084 by -¥5.434.
        Is Peptidream Inc. overvalued?
        According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Peptidream Inc. pay dividends?
          Peptidream Inc. does not currently pay dividends.
          What is Peptidream Inc.’s EPS estimate?
          Peptidream Inc.’s EPS estimate is -¥8.88.
            How many shares outstanding does Peptidream Inc. have?
            Peptidream Inc. has 130,010,400 shares outstanding.
              What happened to Peptidream Inc.’s price movement after its last earnings report?
              Peptidream Inc. reported an EPS of -¥2.35 in its last earnings report, missing expectations of ¥3.084. Following the earnings report the stock price went down -2.794%.
                Which hedge fund is a major shareholder of Peptidream Inc.?
                Currently, no hedge funds are holding shares in JP:4587
                ---

                Peptidream Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Company Description

                Peptidream Inc.

                PeptiDream Inc is a biopharmaceutical company, engaged in the research and development of new pharmaceutical candidates. It discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics using its Peptide Discovery Platform System. The company aspires to be a leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide.
                ---

                4587 Stock 12 Month Forecast

                Average Price Target

                ¥3,281.34
                ▲(21.80% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1255":"¥1,255","2318":"¥2,318","3381":"¥3,381","1786.5":"¥1,786.5","2849.5":"¥2,849.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3380.943993746084,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.38K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3281.33856444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.28K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3182.064935290432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.18K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1255,1786.5,2318,2849.5,3381],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Dec<br/>2024","25":"Dec<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2810,2853.9187687496988,2897.8375374993975,2941.7563062490963,2985.675074998795,3029.593843748494,3073.5126124981925,3117.4313812478913,3161.35014999759,3205.268918747289,3249.1876874969876,3293.1064562466863,3337.025224996385,{"y":3380.943993746084,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2810,2846.2568126492306,2882.5136252984616,2918.7704379476922,2955.0272505969233,2991.284063246154,3027.5408758953845,3063.7976885446155,3100.054501193846,3136.311313843077,3172.568126492308,3208.8249391415384,3245.0817517907694,{"y":3281.33856444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2810,2838.6203796377254,2867.240759275451,2895.8611389131765,2924.4815185509024,2953.1018981886277,2981.722277826353,3010.342657464079,3038.9630371018043,3067.5834167395296,3096.2037963772555,3124.824176014981,3153.4445556527066,{"y":3182.064935290432,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1486.5,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1256,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1533.5,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1426,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2081,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1843,"date":1715904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2087,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2510,"date":1720137600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2492,"date":1722556800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2524,"date":1725580800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2836,"date":1728000000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2884.5,"date":1731628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2810,"date":1733443200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Arrowhead Pharmaceuticals
                Alnylam Pharma
                Fate Therapeutics
                Ionis Pharmaceuticals
                Peptidream

                Best Analysts Covering 4587

                1 Year
                1 Year Success Rate
                1/1 ratings generated profit
                100%
                1 Year Average Return
                +5.40%
                reiterated a buy rating 19 days ago
                Copying Hidemaru Yamaguchi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +5.40% per trade.
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis